The pharmaceutical company announced that the Fingolimod capsules, which are used to treat multiple sclerosis, have entered the American market.
The generic form of Novartis Pharmaceuticals Corporation’s Gilenya capsules, 0.5 mg, is called fingolimod capsules.
For the twelve months ending in September 2022, IQVIA sales data show that the market for Gilenya capsules, 0.5 mg, generated annual sales of almost $1.8 billion.
Sanjeev Krishan, president of Glenmark North America, commented on the announcement and stated, “We are happy to introduce a less expensive substitute for Gilenya Capsules, 0.5 mg to the market. This launch reaffirms our dedication to offering consumers high-quality, reasonably priced pharmaceutical products.”
The present portfolio of Glenmark Pharmaceuticals includes 176 medications that are allowed to be sold in the US market as well as 47 ANDAs that are waiting for FDA approval. Glenmark continues to look for and investigate external development partnerships in addition to these internal filings to strengthen and hasten the expansion of its current pipeline and portfolio.